Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plasma concentrations, efficacy, and toxicity in fibrotic interstitial lung disease
NL-OMON49088Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nintedanib in pulmonary fibrosis (PF), idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and 1 more, sponsored by Erasmus MC. Started Aug 2020; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on NL-OMON49088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49088.